Search

Cyd dengue virus serotype 2 live (attenuated) antigen

Miglustat

Miglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease. … However, clinical experience with miglustat showed that therapeutic levels of the drug could not be achieved in patients without a high incidence of adverse effect.

Varicella zoster vaccine (recombinant)

PHN can last for days, months, or even years following resolution of shingles. … One of the most common complications associated with shingles is the development of Post-Herpetic Neuralgia (PHN), a persistant severe nerve pain that develops as a result of chronic pain from shingles

Sodium tartrate

Sodium tartrate is a disodium salt of l-( + )-tartaric acid that is identified by transparent, colorless, and odorless crystals. It is obtained as a byproduct of wine manufacturing. … Sodium tartrate is generally recognized as safe (GRAS) as a direct human food ingredient. It acts as an emulsifier and pH control agent in food products [L2590].

Kanamycin

Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections.

Isosorbide

Refer to these drug entries for more information. … Isosorbide was previously available in an oral formulation for the reduction of intraocular pressure. It was approved by the FDA in 1980, but has since been discontinued.

Multipotent adult arogenitor cells

The cells for creation of the product are isolated from a qualified donor and expanded on a large scale and then frozen until use. After administration, the cells are cleared from the body over time. … They have immunomodulatory and pro-angiogenic properties while also being mostly non-immunogenic.

Phenolsulfonphthalein

Phenolsulfonphthalein or otherwise called phenol red is a pH indicator commonly used in cell biology laboratories. … Phenolsulfonphthalein is being investigated for use clinically due to its weak estrogen mimicking actions [A174964].

Brensocatib

[A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813] … [A274348] Brensocatib is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor that inhibits neutrophil serine proteases, addressing a key driver of this inflammation.

Ofloxacin

A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.